RJFSA
ALNY icon

Raymond James Financial Services Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.97M Buy
10,786
+8,589
+391% +$2.24M ﹤0.01% 1511
2024
Q2 		$534K Sell
2,197
-910
-29% -$144K ﹤0.01% 2488
2024
Q1 		$464K Buy
3,107
+810
+35% +$135K ﹤0.01% 2575
2023
Q4 		$440K Sell
2,297
-41
-2% -$6.98K ﹤0.01% 2504
2023
Q3 		$414K Sell
2,338
-40
-2% -$7.63K ﹤0.01% 2438
2023
Q2 		$452K Sell
2,378
-2,389
-50% -$474K ﹤0.01% 2404
2023
Q1 		$955K Sell
4,767
-380
-7% -$79.9K ﹤0.01% 1922
2022
Q4 		$1.22M Sell
5,147
-1,200
-19% -$256K ﹤0.01% 1711
2022
Q3 		$1.27M Sell
6,347
-5,532
-47% -$1.06M ﹤0.01% 1685
2022
Q2 		$1.73M Buy
11,879
+29
+0.2% +$4.11K ﹤0.01% 1521
2022
Q1 		$1.94M Buy
11,850
+1,017
+9% +$155K ﹤0.01% 1510
2021
Q4 		$1.84M Buy
10,833
+520
+5% +$96.6K ﹤0.01% 1596
2021
Q3 		$1.95M Buy
10,313
+528
+5% +$99K ﹤0.01% 1500
2021
Q2 		$1.66M Buy
9,785
+2,583
+36% +$378K ﹤0.01% 1602
2021
Q1 		$1.02M Buy
7,202
+5,292
+277% +$796K ﹤0.01% 1855
2020
Q4 		$248K Buy
1,910
+214
+13% +$28.6K ﹤0.01% 2574
2020
Q3 		$247K Buy
1,696
+19
+1% +$2.7K ﹤0.01% 2401
2020
Q2 		$248K Sell
1,677
-500
-23% -$67.4K ﹤0.01% 2353
2020
Q1 		$237K Buy
2,177
+12
+0.6% +$1.39K ﹤0.01% 1981
2019
Q4 		$249K Buy
+2,165
New +$216K ﹤0.01% 2437
2018
Q4 		– Sell
-8,693
Closed -$761K – 2572
2018
Q3 		$761K Buy
+8,693
New +$874K ﹤0.01% 1642

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial Services Advisors's ALNY Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 391% in Q3 2024, buying an estimated $2.24M and bringing the position to 10,786 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

Raymond James Financial Services Advisors first reported a position in ALNY in Q3 2018 and has held it in 21 quarters since. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • Raymond James Financial Services Advisors held 10,786 shares of Alnylam Pharmaceuticals worth $2.97M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 8,589 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $2.24M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1511 holding.
  • Raymond James Financial Services Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 21 quarters since.
  • 567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.